Skip to content

Author

Yan-Fen Fang

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8+ T-cell effector function.

BACKGROUND AND PURPOSE Antiangiogenic multikinase inhibitors (AAMKIs) with PD-1/PD-L1 blockade have been approved to treat certain solid tumours. Their synergy mechanisms remain largely unknown. AL3810 (lucitanib), a AAMKI in Phase II trials, has demonstrated clinical activity. We aim to elucidate the immune modulatory...

Kun Fang, Wen-Xin Zhang, Zi-Han Li et al. · 0 citations
Open access Aug 2026

Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy.

A series of new CDK9/EZH2 dual-target inhibitors are designed by conjugating a self-designed CDK9-targeting fragment with a selective EZH2 inhibitor, and compound A9 demonstrated excellent inhibitory activity.

Yixue Han, Ruiqi Wang, Lina Tian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.